Haleon (HLN) Return on Assets (2023 - 2026)

Haleon's (HLN) quarterly Return on Assets came in at 0.0% in Q2 2026, down 67.2% on a QoQ basis from 0.0% in Q4 2025.

Haleon (HLN) Return on Assets (2023 - 2026) Analysis & Trends

Haleon (HLN) has 4 years of Return on Assets data on file, last reported at 0.0% in Q2 2026.

Quarterly Return on Assets changed N/A year-over-year to 0.0% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.0% (changed N/A YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
Return on Assets declined to 0.0% in Q2 2026, from 0.0% in the prior quarter.
In the past five years, Return on Assets ranged from a high of 0.0% in Q4 2023 to a low of 0.0% in Q2 2026.
A 4-year average of 0.0% and a median of 0.0% in 2025 frame the typical range for Return on Assets.
The widest YoY moves for Return on Assets: up 0 bps in 2024, down 0 bps in 2024.
Tracing HLN's Return on Assets over 4 years: stood at 0.0% in 2023, then tumbled by 51 bps to 0.0% in 2024, then gained by 13 bps to 0.0% in 2025, then tumbled by 67 bps to 0.0% in 2026.
The last three Return on Assets figures came in at 0.0% (Q2 2026), 0.0% (Q4 2025), and 0.0% (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROA (Qtr)
1	Haleon	43.94 Bn	42.97 Bn	-	0.00%
2	Teva Pharmaceutical Industries	42.95 Bn	39.30 Bn	2.15 Bn	0.00%
3	Zoetis	31.58 Bn	29.90 Bn	1.05 Bn	0.00%
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	0.00%
5	United Therapeutics	22.16 Bn	19.49 Bn	683.80 Mn	0.00%
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn	0.00%
7	Neurocrine Biosciences	15.53 Bn	15.14 Bn	935.80 Mn	0.00%
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	0.00%
9	Dr Reddys Laboratories	10.11 Bn	9.95 Bn	-	0.00%
10	Alkermes	8.12 Bn	7.46 Bn	397.90 Mn	0.00%

Download Data